Suppr超能文献

小鼠脑中囊泡单胺转运体2(VMAT2)的免疫化学定位

Immunochemical localization of vesicular monoamine transporter 2 (VMAT2) in mouse brain.

作者信息

Cliburn Rachel A, Dunn Amy R, Stout Kristen A, Hoffman Carlie A, Lohr Kelly M, Bernstein Alison I, Winokur Emily J, Burkett James, Schmitz Yvonne, Caudle William M, Miller Gary W

机构信息

Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA 30322, United States.

Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA 30322, United States.

出版信息

J Chem Neuroanat. 2017 Oct;83-84:82-90. doi: 10.1016/j.jchemneu.2016.11.003. Epub 2016 Nov 9.

Abstract

Vesicular monoamine transporter 2 (VMAT2, SLC18A2) is a transmembrane transporter protein that packages dopamine, serotonin, norepinephrine, and histamine into vesicles in preparation for neurotransmitter release from the presynaptic neuron. VMAT2 function and related vesicle dynamics have been linked to susceptibility to oxidative stress, exogenous toxicants, and Parkinson's disease. To address a recent depletion of commonly used antibodies to VMAT2, we generated and characterized a novel rabbit polyclonal antibody generated against a 19 amino acid epitope corresponding to an antigenic sequence within the C-terminal tail of mouse VMAT2. We used genetic models of altered VMAT2 expression to demonstrate that the antibody specifically recognizes VMAT2 and localizes to synaptic vesicles. Furthermore, immunohistochemical labeling using this VMAT2 antibody produces immunoreactivity that is consistent with expected VMAT2 regional distribution. We show the distribution of VMAT2 in monoaminergic brain regions of mouse brain, notably the midbrain, striatum, olfactory tubercle, dopaminergic paraventricular nuclei, tuberomammillary nucleus, raphe nucleus, and locus coeruleus. Normal neurotransmitter vesicle dynamics are critical for proper health and functioning of the nervous system, and this well-characterized VMAT2 antibody will be a useful tool in studying neurodegenerative and neuropsychiatric conditions characterized by vesicular dysfunction.

摘要

囊泡单胺转运体2(VMAT2,SLC18A2)是一种跨膜转运蛋白,它将多巴胺、5-羟色胺、去甲肾上腺素和组胺包装到囊泡中,为神经递质从突触前神经元释放做准备。VMAT2的功能及相关囊泡动力学与氧化应激、外源性毒物易感性以及帕金森病有关。为了解决近期常用的VMAT2抗体匮乏的问题,我们制备并鉴定了一种新型兔多克隆抗体,该抗体针对与小鼠VMAT2 C末端尾巴内抗原序列相对应的19个氨基酸表位产生。我们利用VMAT2表达改变的遗传模型来证明该抗体能特异性识别VMAT2并定位于突触囊泡。此外,使用这种VMAT2抗体进行免疫组织化学标记产生的免疫反应性与预期的VMAT2区域分布一致。我们展示了VMAT2在小鼠脑单胺能脑区的分布,特别是中脑、纹状体、嗅结节、多巴胺能室旁核、结节乳头体核、中缝核和蓝斑。正常的神经递质囊泡动力学对于神经系统的正常健康和功能至关重要,这种经过充分表征的VMAT2抗体将成为研究以囊泡功能障碍为特征的神经退行性和神经精神疾病的有用工具。

相似文献

1
Immunochemical localization of vesicular monoamine transporter 2 (VMAT2) in mouse brain.
J Chem Neuroanat. 2017 Oct;83-84:82-90. doi: 10.1016/j.jchemneu.2016.11.003. Epub 2016 Nov 9.
4
Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system.
Front Neuroendocrinol. 1998 Jul;19(3):187-231. doi: 10.1006/frne.1998.0168.
5
A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport.
J Neurosci Methods. 2012 Aug 15;209(2):357-66. doi: 10.1016/j.jneumeth.2012.06.002. Epub 2012 Jun 12.
6
Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity.
ACS Chem Neurosci. 2015 May 20;6(5):790-9. doi: 10.1021/acschemneuro.5b00010. Epub 2015 Mar 9.
7
Differential expression of two vesicular monoamine transporters.
J Neurosci. 1995 Sep;15(9):6179-88. doi: 10.1523/JNEUROSCI.15-09-06179.1995.

引用本文的文献

1
Tricyclic and tetracyclic antidepressants upregulate VMAT2 activity and rescue disease-causing VMAT2 variants.
Neuropsychopharmacology. 2024 Oct;49(11):1783-1791. doi: 10.1038/s41386-024-01914-2. Epub 2024 Jul 26.
10
Ambient Light Regulates Retinal Dopamine Signaling and Myopia Susceptibility.
Invest Ophthalmol Vis Sci. 2021 Jan 4;62(1):28. doi: 10.1167/iovs.62.1.28.

本文引用的文献

1
Selective Enhancement of Dopamine Release in the Ventral Pallidum of Methamphetamine-Sensitized Mice.
ACS Chem Neurosci. 2016 Oct 19;7(10):1364-1373. doi: 10.1021/acschemneuro.6b00131. Epub 2016 Aug 18.
3
Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration.
Exp Neurol. 2016 Jan;275 Pt 1(Pt 1):17-24. doi: 10.1016/j.expneurol.2015.09.016. Epub 2015 Sep 30.
5
Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity.
ACS Chem Neurosci. 2015 May 20;6(5):790-9. doi: 10.1021/acschemneuro.5b00010. Epub 2015 Mar 9.
6
Dopaminergic and glutamatergic microdomains in a subset of rodent mesoaccumbens axons.
Nat Neurosci. 2015 Mar;18(3):386-92. doi: 10.1038/nn.3945. Epub 2015 Feb 9.
7
VMAT2 and Parkinson's disease: harnessing the dopamine vesicle.
Expert Rev Neurother. 2014 Oct;14(10):1115-7. doi: 10.1586/14737175.2014.960399. Epub 2014 Sep 14.
8
Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo.
Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9977-82. doi: 10.1073/pnas.1402134111. Epub 2014 Jun 16.
10
Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.
Neuropharmacology. 2014 Jan;76 Pt A(0 0):97-105. doi: 10.1016/j.neuropharm.2013.08.033. Epub 2013 Sep 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验